Previous Close | 33.71 |
Open | 34.69 |
Bid | 33.61 x 0 |
Ask | 33.65 x 0 |
Day's Range | 33.23 - 34.04 |
52 Week Range | 21.60 - 35.49 |
Volume | |
Avg. Volume | 16,551,560 |
Market Cap | 53.926B |
Beta (5Y Monthly) | 0.04 |
PE Ratio (TTM) | 19.46 |
EPS (TTM) | 1.73 |
Earnings Date | N/A |
Forward Dividend & Yield | 0.62 (1.76%) |
Ex-Dividend Date | May 15, 2023 |
1y Target Est | 41.38 |
Chinese drugmaker Sichuan Kelun Pharmaceutical Co said on Monday that Merck & Co Inc was abandoning the joint development of two candidate cancer drugs which have yet to start clinical trials. Representatives for Merck did not immediately respond to a Reuters request for comment. The move comes days after Merck said it would pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs in a deal that could be worth up to $22 billion for the Japanese firm.